A retroviral vector (N2-SV-GC) was constructed by inserting a normal human glucocerebrosidase (GC) cDNA under control of the SV40 early region promoter into the Moloney murine leukemia virus-derived N2 vector. N2-SV-GC produced human GC in murine 3T3 fibroblasts at levels in the range of the endogenous murine GC as determined by enzymatic assay and Western blot analysis. The N2-SV-GC retroviral vector was used for studies of gene transduction of murine hematopoietic progenitor cells (HPC). Infection of bone marrow cultured for 2 to 10 days in medium containing hematopoietic growth factors was significantly more efficient than infection of freshly isolated marrow cells (24% to 32% 6418-resistant CFU-GM Y 15%. respec-AUCHER'S DISEASE is the most prevalent human G lysosomal storage disorder.' Inherited deficiency of the lyososmal enzyme glucocerebrosidase (GC) is responsible for the accumulation of complex glycolipids in macrophages throughout the reticuloendothelial system. The lipid storage results in characteristic hepatosplenomegaly, hypersplenism, and lytic lesions in bone. Gaucher's disease is clinically heterogenous and may be subdivided into non-neuronopathic (type l), acute neuronopathic (type 2), and sub-acute neuronopathic (type 3) forms. Allogeneic bone marrow transplantation (BMT) has been shown to have a beneficial effect on the course of the disease in patients with the non-neuronopathic form of Gaucher's d i~e a s e .~-~ However, application of BMT to patients with Gaucher's disease is limited by the lack of histocompatible sibling donors for the majority of patients. The cloning of normal copies of the human GC gene permits consideration of gene replacement therapy for Gaucher's disease.'V6 Retroviral vectors derived from Moloney murine leukemia virus (MoMuLV) are under investigation for their ability to stably introduce normal human genes into hematopoietic stem cells for the genetic correction of inherited diseases.' Expression of a number of genes relevant to clinical gene therapy (eg, &globin, adenosine deaminase) has been achieved in murine CFU-S and long-term reconstituted transplanted mice.'." Previous studies demonstrated efficient retroviral vector-mediated transfer of the human GC gene into fibroblasts and B-lymphoblastoid cell lines from Gaucher's GC gene transduction resulted in the production of normal levels of GC enzymatic activity in the genetically deficient cells.
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We used long-term bone marrow culture (LTBMC) to study gene transduction of primary murine hematopoietic progenitor cells (HPC) by a GC gene retroviral vector (N2-SV-GC). LTBMC, first described by Dexter et al," mimics the bone marrow microenvironment with an adherent stromal layer of macrophages, fibroblasts, endothelial cells, and adipocytes supporting continuous proliferation and differentiation of loosely adherent primitive HPC. Maintaining hematopoietic cells in LTBMC after retroviral vectormediated gene transfer allowed serial analyses to be performed of gene expression in the hematopoietic progenitors and progeny cells. Our results show an increased rate of GC tively). The marrow infected by N2-SV-GC was maintained in long-term bone marrow culture (LTBMC) and had a stable level of 6418-resistant HPC over 2 months of serial assays. The human GC gene of the vector was persistently expressed in the nonadherent cell fraction of the murine LTBMC as determined by Northern blotting, Western blotting, and immunohistochemical staining using a monoclonal antibody specific for human GC. N2-SV-GC also expressed the human GC gene in day 12 CFU-S. LTBMC represents a novel system for retroviral vector-mediated gene transduction of HPC and may accurately predict the activities of vectors in vivo. 0 7990 by The American Society of Hematology.
gene transfer into murine bone marrow after preculture with hematopoietic growth factors and stable expression of the human GC gene in the progeny hematopoietic cells. packaging cells with 8 pg/mL polybrene. Psi2 clones were obtained by selection in 0.5 mg/mL of G418, and the titers of vector produced by each clone were determined with 3T3 cells. One clone of Psi2 cells producing N2-SV-GC with a titer of 5 x lo6 G418-resistant U/mL was used for subsequent studies. The N7 clone of PA317 cells producing the N2 vector was obtained from W. French Anderson (National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD).
Vector virus-containing supernatants were prepared by removing the medium from subconfluent 100-mm plates of VPF and adding 10 mL of IMDM-20 (Iscove's modified Dulbecco's medium [IMDM] with 20% HI-FCS, 2 mmol/L glutamine, 100 U/mL penicillin, and 100 pg/mL streptomycin). Medium was collected after 18 to 24 hours, filtered through a 0.45 pm filter, and stored at -7OOC. Assays to detect helper virus were performed by the S+,L-assay and by analysis for helper-rescued vector. For the latter assay, culture supernatants were added to fresh 3T3 cells, which were then serially passaged for 2 weeks. Culture medium was collected from the supernatant-exposed 3T3 cells at 4, 7, 10, and 14 days after attempted infection, and applied to secondary 3T3 cells, which were then grown in G418. We did not detect helper virus by either assay from the Psi2 N2-SV-GC VPF, or from N2-SV-GC-infected LTBMC, sampled 3 days after the medium was changed, at 1 and 8 months after vector infection. The N7 VPF did produce helper virus at a titer of approximately 1 x 10'.
Establishment and Growth of Murine LTBMC
Bone marrow was harvested from 6-to 8-week-old C57BL/6J (B6) mice (Jackson Laboratories, Bar Harbor, ME) by flushing the marrow cavities of the femurs and tibiae from the donors with cold RPMI medium containing penicillin (100 U/mL) and streptomycin (100 pg/mL). The cells were washed once with RPMI-10% FCS, resuspended in IMDM, and viable cell numbers determined with trypan blue. To establish LTBMC, 1 x lo7 nucleated cells were placed into T25 vented filter-top flasks (Costar, Cambridge, MA) in complete bone marrow medium (CBMM). CBMM is IMDM, 30% HI-FCS; 1% deionized bovine serum albumin (BSA); mol/L hydrocortisone; 1 x mol/L 2-mercaptoethanol; 2 mmol/L glutamine; 100 U/mL penicillin, 100 pg/mL streptomycin; and hematopoietic growth factors provided as 5% (vol/vol) of IMDM-20 conditioned by WEHI-3B (WEHI-CM) and 5% (vol/vol) of IMDM-20 conditioned for 7 days by murine spleen cells stimulated with 2.5 pg/mL pokeweed mitogen (PWM-CM).
To maintain the LTBMC, half of the culture medium and nonadherent cells were replaced with fresh CBMM every 5 to 7 days. These LTBMC have been maintained for over 10 months with sustained production of hematopoietic progenitors (assayed in the CFU-GEMM colony assay) and mature blood cells (determined by Wright-Geimsa staining of cytocentrifuge preparations).
CFU-GEMM Methylcellulose Colony Assay
Hematopoietic colonies were grown from murine bone marrow by mixing cells with or without 1 .O mg/mL G418 (based on manufacturer's reported bioactivity) in 3 mL of CBMM (which includes 5% WEHI-CM and 5% PWM-CM) with 0.9% methylcellulose in 5-mL tubes. One-milliliter duplicates containing 1 x los nucleated cells were plated in gridded 35-mm tissue culture dishes (Lux, Bountiful, UT). Colonies were scored 14 days after plating by standard morphologic riter ria?^ Clusters of 240 cells were categorized as either BFU-E if they consisted of bursts of hemoglobinized cells, CFU-GM if they contained only nonhemoglobinized cells, or CFU-GEMM, which contained both hemoglobinized and nonhemoglobinized cells. Wright-Geimsa-stained cytocentrifuge examination of individual CFU-GEMM show them to contain macrophages, granulocytes, eosinophils, erythrocytes, and occasional megakaryocytes.
Comparison between the percentages of (3418-resistant colonies were analyzed by Fisher's Exact Test.
Retroviral Vector Infection of Murine Bone Marrow
Retroviral vector infections of the murine bone marrow cells in LTBMC were performed by collecting the medium and nonadherent cells, pelletting the cells, and resuspending them in 10 mL of vector virus-containing supernatant supplemented with 5% WEHI-CM, 5% PWM-CM, and 4 pg/mL polybrene. The cells and virus were then replaced on the adherent stromal layer and the flasks were incubated at 37°C for 2 hours. Nonadherent cells were collected, washed two times with HBSS to remove polybrene, and replaced in their flasks in fresh CBMM.
Analysis of Transfer and Expression of Human GC by N2-SV-GC in Day 12 CFU-S
Freshly obtained nucleated bone marrow cells, 1 x lo7, were cocultured in CBMM on 100-mm dishes of subconfluent, irradiated (3,000 cGy) N2-SV-GC VPF for 48 hours in the presence of polybrene (4 pg/mL). Marrow cells were then washed twice with HBSS and recultured for an additional 24 hours with 1.0 mg/mL G418 in CBMM. Cells were washed twice with HBSS and resuspended in IMDM at 0.5 to 1.0 x lo7 cells/mL. Marrow was injected, in a volume of 0.1 mL, into the tail veins of syngeneic mice, irradiated with 1,050 cGy in fractions of 650 and 400 cGy spaced 6 to 18 hours apart. Recipient spleens were removed 12 days after marrow injection and the CFU-S were isolated under a dissecting microscope and divided into two portions for paired Southern and Northern blot analysis.
Southern and Northern Blot Analysis
Genomic DNA was isolated from cells by the salting-out method" and digested with XbaI under the conditions recommended by the manufacturer (Bethesda Research Laboratories, Bethesda, MD). Total cellular RNA was isolated by the acid guanidinium thiocyanatephenol chloroform method as described.26 Electrophoresis and transfer to Biotrace nylon membranes (Gelman, Ann Arbor, MI) were performed as described?' Hybridization probes were either the full-length GC cDNA or the neo gene (from pBRneo), labeled with '2P-a-dCTP by the random-priming method.28 Hybridizations were performed as described29 at 65OC overnight, followed by washes in 0.1 to 0.3X SSC-O.l% SDS at 65OC for 1 hour. Autoradiography was performed with XAR film (Kodak, Rochester, NY) at -70°C.
GC Enzymatic Assay
3T3 murine fibroblasts, obtained from the American Type Culture Collection (Rockville, MD), were infected with N2-SV-GC virus-containing supernatants and selected in 0.5 mg/mL (3418 for 1 week. Fibroblasts for GC enzymatic assay were trypsinized, washed twice with HBSS, and lysed in "sonication buffer" (50 mmol/L potassium phosphate buffer, pH 6.5 with 0.25% Triton X-100). Samples were sonicated for two 30-second pulses at 40 watt-seconds and centrifugated at 12,000 RPM for 2 minutes at 4OC. The protein concentration of the cleared sonicate was determined with the Pierce BSA kit (Rockford, IL) using BSA for construction of a standard curve.
For each cell sample, measurements of GC enzymatic activity were made of both total GC activity (representing the endogenous murine GC activity and any human GC activity resulting from gene transfer) and the activity remaining after immunoprecipitation of the human enzyme with the 8E4 monoclonal antibody (MoAb)," specific for human GC (representing the endogenous murine activity only). Each sample was divided into two identical aliquots and the human GC was immunoprecipitated from one of each pair. Ten micrograms of protein of each cleared sonicate in 50 pL of sonication buffer were mixed with either 10 pL of 8E4 MoAb at 10 pg/mL in sonication buffer (for immunoprecipitation of human GC) or 10 pL of sonication buffer alone (for determination of total GC activity) and shaken at 4OC for 1 hour. Twenty-five microliters of Staph. aureus Cowan strain protein A (Pansorbin-Calbiochem, San Diego, CA) was then added to each sample, which were inverted overnight at 4OC. Samples were spun at 12,000 x g for 2 minutes and aliquots of supernatant removed for measurement of GC enzymatic activity.
GC enzymatic activity was measured by the method of 
Western Blot Analysis
Cell lysates were prepared for Western blotting by the same procedure that was used for GC enzyme assays. Thirty micrograms of each cleared sonicate was loaded into the well of a 10% polyacrylamide-SDS gel. All subsequent steps were performed at room temperature. Samples were electrophoresed and transferred to a nitrocellulose membrane by electrical current. Nonspecific protein binding was blocked by shaking the blot for 1 hour in tris-buffered saline (TBST 100 mmol/L tris, pH 8.0; 150 mmol/L NaCI; 0.05% Tween 20) with 3% gelatin (Bio-Rad, Richmond, CA). The human GC protein was detected by successive I-hour incubations in the murine MoAb 8E4 (Ipg/mL), biotinylated goat anti-murine immunoglobulin G (IgG) (Tago, Burlingame, CA), and streptavidinconjugated alkaline phosphatase (Tago), each in TBST with 1% gelatin. The blot was washed three times by shaking in TBST for 10 minutes between each antibody incubation. Bound enzyme was detected by soaking in 0.2 mg/mL nitroblue tetrazolium and 0.05 mg/mL 5-bromo-4-chloto-3-indoylphosphate ptaluidine (BCIP) (Sigma, S t Louis, MO) in 100 mmol/L tris, pH 9.8; 100 mmol/L NaCI; and 5 mmol/L MgCI,. The colorimetric reaction was stopped by multiple washes with distilled water.
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Immunohistochemistry to Identijy Single-cell Expression of Human GC
Nonadherent cells were removed from LTBMC, washed two times with HBSS, resuspended in two drops of phosphate buffered saline (PBS) with 50% FCS, and cytocentrifuged onto glass slides at 940 rpm for 4 minutes. The cells were fixed by immersion of the slides in methanol for 20 minutes, followed by a wash in PBS. Nonspecific peroxidase and antibody binding were blocked by incubation at room temperature in 10% hydrogen peroxide in methanol for 10 minutes and then in a 1:1 mixture of human gammaglobulin (Cutter, Elkhart, IN) and horse serum for 20 minutes. Antibody staining was performed at 37OC using the 8E4 MoAb (10 pg/mL), biotinylated goat anti-mouse IgG (1: 1 ,OOO), and avidin-biotin-peroxidase complex, as described by the manufacturer (Vector, Burlingame, CA). Antibodies were in PBS and the slides were washed with PBS for 10 minutes at room temperature between each successive antibody. Positive cells were identified by staining with the alkaline phosphatase substrate 4-aminoethyl carbozol. The cells were then counterstained with hematoxylin.
RESULTS
Function of the N2-SV-GC Vector in Murine 3T3
Fibroblasts .
The retroviral vector NZSV-GC, constructed to transfer the human GC gene, is shown in Fig 1. Expression of the GC gene is under transcriptional control of the SV40 early region promoter/enhancer, and the neo gene is transcribed from the MoMuLV long-terminal repeat (LTR) promoter/enhancer. Vector function may be followed by the encoded neomycin resistance activity and the production of human GC.
Transfer and expression of the human GC gene by NZSV-GC was first characterized using murine 3T3 fibroblasts as the cell target. 3T3 cells infected by N2-SV-GC and selected in the neomycin analogue G418 contained levels of total GC enzymatic activity that are approximately twice that of nontransduced 3T3 cells (826.5 U v 364.0 U, respectively) (Fig 2) . The majority of the increment of GC activity in the NZSV-GC-infected 3T3 cells is immunoprecipitated by the MoAb 8E4, consistent with it being contributed by the human GC gene. The specificity of the 8E4 antibody for human GC is demonstrated by the immunoprecipitation of more than 90% of the GC activity from human fibroblasts and less than 5% of the GC from murine fibroblasts. Western blot analysis shows that 3T3 cells infected by N2-SV-GC have immunoreactive protein of an identical pattern to the native GC of human fibroblasts (Fig 3) . Thus, the N2-SV-GC vector fulfills the basic function of transfer and expression of the human GC gene in murine 3T3 fibroblasts.
Comparison of Methods to Achieve High Rates of Gene Transfer by the N24V-GC Vector in Primary Murine Hematopoietic Cells
To study hematopoietic progenitor cell transduction. murine bone marrow was infected with the N2-SV-GC vector and maintained in LTRMC. We first sought to determine whether the precultureof murine marrow in medium containing hematopoietic growth factors would facilitate retroviral vector infection of the HPC. We were performed for each set of cells by an identical procedure using frozen aliquots with q u a l viral titers from a pool of N2-SV-GC vector virus supernatant. The day after vector infection. samples were plated in methylcellulose for determination of the percentage of (3418-resistant progenitors. and the remainder of the marrow was then maintained in LTRMC.
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The results confirm that preculturing marrow in medium containing hematopoietic growth factors produces an increased rate of retroviral vector-mediated gene transfer. Table I shows the numbers and percentages of G418-resistant hematopoietic colonies produced from samples analyzed directly after vector infection in three separate experiments. Summation of the data from the three cxperimcnts allows analysis based on 6 x IO' nucleated marrow cells for each infection condition. The marrow that was infected immediately after removal from the donors produced a modest peicentage of G4I8-resistant CFU-GM G418. The marrow that was cultured with growth factors for z z 2 days before infection yielded a significantly higher percent-I I age of G418-resistant colonies (24.2%) than freshly infected marrow ( P = .031). Infection of the marrow cultured with growth factor-containing medium for IO days produced a higher rate of G418-resistant CFU-GM progenitors (32.3%) ( P = .OOO12 v unstimulated: P = .096 v day 2 infected). The numbers of RFU-E and CFU-GEMM were too few to allow meaningful comparisons, although again it can be seen that uninfectcd bone marrow was completely inhibited from colony formation by 1.0 mg/mL G418 and that retroviral vector infection produced moderate numbers of G418-resistant colonies.
To analyze the vector transduction of long-lived hematopoietic progenitors. the remainder of the cells from each set of infection condition were maintained in LTRMC. Nonadherent cells from these LTRMC were subsquently withdrawn for serial assays of G4 IS-resistant progenitors. Analysis of CFU-GM at I and 2 months after infection with N2-SV-GC showed persistent ne0 gene expression in the bone marrow cells maintained in LTRMC (Table 2 ). The marrow infected after IO days of culture maintained the highest level of (3418-resistant CFU-GM over the subsequent 2 months of culture (42% to 44%). Similarly, the percentages of G418-resistant RFU-E and CFU-GEMM. obtained by sampling . that preculturing bone marrow in the presence of hematopoi- 
etic growth factors results in enhanced retroviral vector infection of long-lived hematopoietic progenitors.
Assessment of Expression of the Human GC Gene by
Murine LTBMC Transduced by N2-SV-GC
To determine whether the murine LTBMC infected with the N2-SV-GC vector also express the human GC gene, the entire LTBMC were selected in G418 to produce cultures composed only of cells containing the vector sequences. Murine LTBMC were infected with N2-SV-GC supernatant, 2 and 10 days after culture initiation, and 1.0 mg/mL G418 was added 4 to 7 days later. Uninfected LTBMC were killed by this concentration of G418. Vector-infected cultures suffered 50% to 75% decreases in both stromal and 'Sum of colonies from duplicate plates representing 2 x lo5 nucleated cells. Marrow, infected with N2-SV-GC (from Table 1 , Experiment 1). was maintained in LTBMC. Samples were plated for colony assay on the day after vector infection (day 1) and after 30 and 60 days in LTBMC without G4 18 selection of the LTBMC. (+)G418 at 1 .O mg/mL in colony assay. nonadherent cells after addition of (3418. but over the subsequent 2 to 4 weeks, both cell populations became replenished. After G418 selection and reconstitution of the LTRMC. a high percentage of G4I8-resistant CFU-GM progenitors (747 to 94%) are consistently seen (Table 3) .
Southern blot analysis of the retroviral vector-infected. G4IX-selected murine LTRMC confirms the presence of intact proviral sequences (Fig 4) . Genomic DNA was isolated from the nonadherent cells of LTRMC 1 month after infection by either N2 or N2-SV-GC and G418 selection. Samples were digested with the endonuclease Xhal. subjected to agarosc gel electrophoresis. and transferred to a nylon membrane for hybriditation. The sample from the N2-SV-GC-infected culture shows the predicted 4.9-kilobase (kb) band hybridizing to both the GC cDNA probe and the neo gene probe (lanes 2 and 4) . DNA from cells infected by the parental N2 vector had a 3.2-kb band detected by the neo probe. but no hybriditation to the human S C probe (lanes 3 and I. respectively). Under the high stringency conditions used for the posthybriditation washes (0.1 X ssc. 0.1% SDS. 65OC). the endogenous murine glucocerebrosidase sequences were not detected by the human GC probe. It is concluded that the rctroviral vectors are present and intact in the genomic DNA of the nonadherent cell fraction from the LTRMC.
Northern blot analysis demonstrates active transcription of the N2-SV-GC vector in murine bone marrow cells maintained in LTRMC for 2 months after vector infection and G4 I8 selection (Fig 5. lane 2) . The three RNA species detected using the human GC cDNA as probe are of the sizes expected from vector transcripts initiated in the LTR and SV40 promoters and the endogenous murine GC mRNA (5.6, 2.6. and 2.0 kb. respectively). The SV40 promoterinitiated transcript was more abundant than the transcript from the LTR in the transduced nonadherent cclls from the LTRMC. The ratio of the vector transcripts (SV40 Y LTR) in LTRMC cells is the converse of that seen in the Psi2 fibroblasts where the LTR-initiated transcript is in far greater abundance (Fig 5. lane I) . The pattern and intensity of vector transcripts was stable in the LTRMC. infected by N2-SV-GC and selected for I week in G4 18. over at least R months of subsequent growth in the absence of further G418 select ion.
Western blot analysis with the 8E4 MoAb demonstrates immunoreactive human GC protein in the N2-SV-GCinfected murine LTRMC with the same apparent molecular weight as the GC from human fibroblasts (Fig 6) . A similar level of human immunoreactive GC protein was detected in samples of nonadherent cells taken as much as 6 monthsafter vector infection. The human GC immunoreactive material is absent from murine LTRMC cells infected by the parental N 2 vector.
An additional confirmation of the production of human GC by individual cells of the LTBMC infected by N2-SV-GC is provided by immunohistochemical staining. Nonadherent cell samples were removed from the LTRMC infected by either N2 or N2-SV-GC and prepared on microscope slides by cytocentrifugation. The cells were incubated with the 8E4 MoAb followed by detection of bound antibody with immunoperoxidase staining. Virtually no reactivity was seen with the murine LTRMC cells infected by the N2 vector (Fig 7A) . In contrast. specific staining demonstrating the presence of human immunoreactive GC was Seen in the LTRMC cells infected with N2-SV-GC (Fig 7B) . Immunoreactive human GC was present in approximately half of the neutrophils. macrophages. and other mononuclear cells. The granular pattern Suggests that the GC is distributed within discrete cellular compartments (vesicles). as would be expected if the GC were contained within lysosomes. 
Expre.wion of Human GC' hy N2-S V-GC' in Primary
Miirine Day 12 CFU-S Finally, we examined expression of the human GC gene in cells derived from the primitive hematopoietic progenitor that produce day I2 CFC-S. Freshly isolated, primary murine bone marrow was infected with the N2-SV-GC vector and injected into irradiated, syngeneic recipients. Individual day 12 CFU-S were divided into two portions 10 permit paired analysis of vector gene transfer (by Southern blot) and vector gene cxpresion (by Northern blot). Figure 8 shows typical results from five such CFU-S. Southern blot analysis detects the endogenous murine genomic GC gene by using the human GC cDNA as the probe followed by relatively low stringency washes in 0.3X SSC at 65OC. Most distinctly seen in focus no. 5. Xhal-digestion of murine genomic DYA produces multiple fragments with approximate molecular weights of 2.4. 2.8 (lightest). 3.8 (darkest). 4.7. and 5.0 kb. From foci no. 2 and 3. an additional darkly hybridizing band is seen. The size of approximately 5.0 kb indicates that it represents the expected Xhal fragment produced from intact. integrated N2-SV-GC proviruses in these CFU-S. Rehybridimtion of the Southern blot with the neo gene probe detected only the 5.0-kb band from foci no. 2 and 3. confirming that it represents vector-derived squenccs (data not shown).
Northern blot analysis of the remaining portion of these same foci shows the endogenous murine GC transcript at 2.0 kb in all samples (although quite weakly in foci no. 3. reflecting a low amount of isolated RNA). Additional transcripts corresponding in size to the 4.9-kb LTR-derived and the 2.6-kb SV40 promoter-derived vector transcripts are seen in foci no. 2. As in the marrow maintained in LTRMC. the SV4O-promoted transcript is in greater abundance than the full-length transcript. We analyzed a total of 28 CFU-S derived from N2-SV-GC-infected marrow and IO (36%) contained intact proviruses. Eight of the foci that contained vector DYA were found to express the N2-SV-GC transcripts in the same pattern and relative abundance. 
DISCUSSION
The results presented here demonstrate high eficiency transfer and persistent expression of the human GC gene by the N2-SV-GC vector in murine hematopoietic cells. The human GC gene was expressed in primary day I 2 CFU-S and in the nonadherent cells of murine LTRMC assayed over 2 to 8 months after N2-SV-GC vector infection. Expression Of the human GC gene in the LTRMC was Confim~d at the levels of both R K A (by Northern blot analysis using the human GC cDNA as probe) and protein (by Western blot analysis of immunoreactive human GC protein in lysates and immunohistochemical staining of single cells). Additionally. the level of G418-resistant hematopoietic progenitors remained relatively constant over 2 months of successive assays. The continued expression of these vector genes demonstrates that stable transduction of renewable progenitor cells has been achieved. Northern blot analysis of the vector transcripts in the CFU-S and nonadherent cells of the LTBMC showed a greater abundance of the transcript from the internal SV40 promoter than from the 5' LTR. In contrast, in 3T3 murine fibroblasts and other cell lines, the LTR-directed transcript of N2-SV-GC is far more abundant than the transcript from the internal SV40 promoter. The ratios of transcript abundances presumably represent differences in promoter activities in these two cell types, although differential R N A stability would also affect the steady state levels. Magli et have previously found that the MoMuLV LTR is a relatively weak promoter in murine CFU-GM, compared with its high activity in fibroblasts.
A Southern
The apparent differences in the activities of the vector promoters in hematopoietic cells compared with 3T3 fibroblasts emphasizes the importance of studying vector gene expression in the specific cell type of interest. Established cell lines have previously been shown to be poor models for assessing the activity of vectors to be used for bone marrow transduction; some vectors that functioned properly in continuous cell lines did not express their gene products after introduction into primary HPC. A primary goal of experimental studies leading to clinical gene therapy is the identification of methods that produce high rates of gene transfer into hematopoietic stem cells. Retroviral vectors efficiently transduce genes in a variety of cell types such as fibroblasts, lymphocytes, and endothelial cells, but the rates of successful gene transfer into hematopoietic cells (especially of primates) have generally been l o~e r .~' -~' One factor that may limit the frequency of retroviral vector gene transduction of HPC is the low percentage of such cells, which are in active cell cycle. 42 Infection by retroviruses requires DNA replication by the target cells to permit proviral integrati0n.4~ Accordingly, a number of protocols have been developed to increase the percentages of vector-transduced hematopoietic progenitor and stem cells. Treatment of marrow donors with 5-fluorouracil, preculture of marrow with hematopoietic growth factors, postinfection selection of marrow with G418, and the use of improved retroviral vectors that yield high titers have led to relatively high rates of gene transfer (in the range of 50% to 80% proviral-containing CFU-S)."-'3. [44] [45] [46] [47] A similarly high rate of transduction of murine HPC in LTBMC by a retroviral vector containing only the neo gene has been reported. 48 These investigators also found that the level of G418-resistant progenitors remained stable when the LTBMC was serially sampled over several months. Schuening et recently demonstrated that the rate of retroviral vector-mediated gene transfer into canine HPC can be increased by multiple rounds of infection of marrow kept in LTBMC.
In accord with these previous reports, we found that the percentage of G418-resistant hematopoietic progenitors was increased by preculture of murine bone marrow cells for 2 to 10 days with hematopoietic growth factors before exposure to the retroviral vector supernatant. Approximately 30% to 40% of the hematopoietic progenitors of the marrow infected after 10 days of preculture produced G418-resistant colonies, a significant increase over the transduction rate of marrow infected without preculture in growth factors. After G418 selection, the LTBMC contained 70% to 90% G418-resistant progenitors.
Interestingly, the bone marrow that was infected after 2 days in culture had a higher percentage of G418-resistant adherent stromal cells than did the cultures infected after 10 days. With the number of bone marrow cells that were inoculated into the flasks, the stromal cells are relatively sparse and actively dividing in 2-day-old cultures but become nearly confluent after 10 days. Presumably, the higher rate of retroviral vector infection of the stromal cells on day 2 reflects the higher percentage of dividing cells. Because a higher number of G418-resistant stromal cells led to quicker reconstitution of the LTBMC after G418 selection, the vector infection protocol that we now follow consists of a round of infection of the culture on day 2 after LTBMC establishment for stromal infection and again on day 10 for optimal hematopoietic progenitor cell infection.
Although we demonstrated gene transfer with sustained expression in long-lived HPC in the LTBMC model, true pluripotent stem cells may not have been transduced. The only definitive assay for such cells is bone marrow transplantation. Spooncer and Dexter" have shown that murine LTBMC not treated with vectors contain sufficient pluripotent stem cells to produce full hematologic reconstitution of lethally irradiated mice.50 Human marrow, cultured for 10 days under similar conditions, has also been shown to produce full hematologic recovery in clinical BMT." BMT using stably transduced LTBMC may provide a useful method to achieve hematopoietic reconstitution with genetically corrected stem cells for the treatment of genetic diseases. Advantages of using long-term cultured marrow for clinical gene transfer/autologous BMT would be the high efficiency of gene transfer obtained in this system and the ability to characterize the extent of gene transduction before transplant of the treated marrow. Further studies on the use of LTBMC for gene therapy are warranted. 
